NDC 0002-1484

MOUNJARO

Tirzepatide

MOUNJARO is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Eli Lilly And Company. The primary component is Tirzepatide.

Product ID0002-1484_47ab0499-a914-4b28-8649-e7e7a6e6912b
NDC0002-1484
Product TypeHuman Prescription Drug
Proprietary NameMOUNJARO
Generic NameTirzepatide
Dosage FormInjection, Solution
Route of AdministrationSUBCUTANEOUS
Marketing Start Date2022-05-13
Marketing CategoryNDA /
Application NumberNDA215866
Labeler NameEli Lilly and Company
Substance NameTIRZEPATIDE
Active Ingredient Strength8 mg/.5mL
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 0002-1484-80

4 SYRINGE in 1 CARTON (0002-1484-80) > .5 mL in 1 SYRINGE (0002-1484-01)
Marketing Start Date2022-05-13
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "MOUNJARO" or generic name "Tirzepatide"

NDCBrand NameGeneric Name
0002-1457MOUNJAROtirzepatide
0002-1460MOUNJAROtirzepatide
0002-1471MOUNJAROtirzepatide
0002-1484MOUNJAROtirzepatide
0002-1495MOUNJAROtirzepatide
0002-1506MOUNJAROtirzepatide

Trademark Results [MOUNJARO]

Mark Image

Registration | Serial
Company
Trademark
Application Date
MOUNJARO
MOUNJARO
97668206 not registered Live/Pending
Eli Lilly and Company
2022-11-08
MOUNJARO
MOUNJARO
97596856 not registered Live/Pending
Eli Lilly and Company
2022-09-19
MOUNJARO
MOUNJARO
97468410 not registered Live/Pending
Eli Lilly and Company
2022-06-21
MOUNJARO
MOUNJARO
88680946 not registered Live/Pending
Eli Lilly and Company
2019-11-05

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.